Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 5
Submit an article Journal homepage
801
Views
13
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis

Athina PapadopoulouDepartment of Neurology, University Hospital Basel, 4031 Basel, Switzerland;Medical Image Analysis Center, University Hospital Basel, 4031 Basel, Switzerland
, MD,
Ludwig KapposDepartment of Neurology, University Hospital Basel, 4031 Basel, Switzerland
, MD &
Till SprengerMedical Image Analysis Center, University Hospital Basel, 4031 Basel, Switzerland;Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland+41 613286386; +41 612654100; [email protected]
, MD (Professor)
Pages 749-759 | Published online: 17 Feb 2015

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Dejan Jakimovski, Caila B Vaughn, Svetlana Eckert, Robert Zivadinov & Bianca Weinstock-Guttman. (2020) Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety 19:9, pages 1121-1142.
Read now
Dirk Deleu, Boulenouar Mesraoua, Beatriz Canibaño, Gayane Melikyan, Hassan Al Hail, Lubna El-Sheikh, Musab Ali, Hassan Al Hussein, Faiza Ibrahim & Yolande Hanssens. (2019) Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview. Current Medical Research and Opinion 35:2, pages 249-260.
Read now
Heather E Moss. (2017) Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown. Eye and Brain 9, pages 13-21.
Read now
Dirk Deleu, Boulenouar Mesraoua, Hisham El Khider, Beatriz Canibano, Gayane Melikyan, Hassan Al Hail, Noha Mhjob, Anjushri Bhagat, Faiza Ibrahim & Yolande Hanssens. (2017) Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. Current Medical Research and Opinion 33:3, pages 439-458.
Read now

Articles from other publishers (9)

. 2020. Diagnostik und Therapie neurologischer Erkrankungen. Diagnostik und Therapie neurologischer Erkrankungen 37 87 .
Moritz Förster, Patrick Küry, Orhan Aktas, Clemens Warnke, Joachim Havla, Reinhard Hohlfeld, Jan Mares, Hans-Peter Hartung & David Kremer. (2019) Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety 42:5, pages 633-647.
Crossref
Luisa Klotz, Joachim Havla, Nicholas Schwab, Reinhard Hohlfeld, Michael Barnett, Stephen Reddel & Heinz Wiendl. (2019) Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Therapeutic Advances in Neurological Disorders 12, pages 175628641983657.
Crossref
David Kremer, Moritz Förster, Clemens Warnke, Joachim Havla & Reinhard Hohlfeld. (2018) Therapie der Multiplen Sklerose: Management der Nebenwirkungen. Deutsches Ärzteblatt Online.
Crossref
P. Soelberg Sorensen. (2017) Safety concerns and risk management of multiple sclerosis therapies. Acta Neurologica Scandinavica 136:3, pages 168-186.
Crossref
Joachim Havla, Clemens Warnke, Tobias Derfuss, Ludwig Kappos, Hans-Peter Hartung & Reinhard Hohlfeld. (2016) Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Ärzteblatt international.
Crossref
L. Klotz, A. Berthele, W. Brück, A. Chan, P. Flachenecker, R. Gold, A. Haghikia, K. Hellwig, B. Hemmer, R. Hohlfeld, T. Korn, T. Kümpfel, M. Lang, V. Limmroth, R. A. Linker, U. Meier, S. G. Meuth, F. Paul, A. Salmen, M. Stangel, B. Tackenberg, H. Tumani, C. Warnke, M. S. Weber, T. Ziemssen, F. Zipp & H. Wiendl. (2016) Monitoring von Blutparametern unter verlaufsmodifizierender MS-TherapieMonitoring of blood parameters under course-modified MS therapy. Der Nervenarzt 87:6, pages 645-659.
Crossref
Rebecca Straus FarberAsaff HarelFred Lublin. (2016) Novel Agents for Relapsing Forms of Multiple Sclerosis. Annual Review of Medicine 67:1, pages 309-321.
Crossref
Rebecca S. Farber & Ilana K. Sand. (2015) Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders 8:5, pages 212-232.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.